공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 요로감염증 시장 : 약제 클래스별(아미노글리코사이드, 아졸, 퀴놀론, B-락탐), 임상 적응증별(방광염, 신우신염, 요도염), 최종사용자별 시장 조사, 예측(-2025년), COVID-19의 누적 영향

Urinary Tract Infection Market Research Report by Drug Class (Aminoglycosides, Azoles, Quinolones, and B-lactam), by Clinical Indication (Cystitis, Pyelonephritis, and Urethritis), by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

리서치사 360iResearch LLP
발행일 2021년 04월 상품 코드 1000970
페이지 정보 영문 184 Pages
가격
US $ 3,949 ₩ 4,531,000 Online Access (Single User License - 1 Year)
US $ 4,949 ₩ 5,678,000 PDF (Single User License) + Excel
US $ 5,949 ₩ 6,826,000 PDF (1-5 User License) + Excel
US $ 7,949 ₩ 9,121,000 PDF (Site License) + Excel
US $ 9,949 ₩ 11,416,000 PDF (Enterprise License) + Excel


세계의 요로감염증 시장 : 약제 클래스별(아미노글리코사이드, 아졸, 퀴놀론, B-락탐), 임상 적응증별(방광염, 신우신염, 요도염), 최종사용자별 시장 조사, 예측(-2025년), COVID-19의 누적 영향 Urinary Tract Infection Market Research Report by Drug Class (Aminoglycosides, Azoles, Quinolones, and B-lactam), by Clinical Indication (Cystitis, Pyelonephritis, and Urethritis), by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19
발행일 : 2021년 04월 페이지 정보 : 영문 184 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 요로감염증 시장 규모는 2020년 71억 2,798만 달러에서 2025년 말까지 94억 8,814만 달러로 성장할 것으로 예상됩니다.

COVID-19는 거의 모든 업계에 영향을 미친 전례 없는 세계적인 공중위생상 긴급사태이기 때문에 예측기간 중 업계의 성장에 장기적인 영향을 미칠 것으로 예측됩니다. 우리가 진행중인 조사는 조사 프레임워크를 증폭하고, 기초가 되는 COVID-19의 문제와 향후 잠재적 방향을 확실히 포함시키고 있습니다. 조사는 소비자의 행동과 수요 변화, 구입 패턴, 공급망 재라우팅, 현재 시장 힘의 역학 및 정부의 중요한 개입을 고려한 COVID-19에 관한 인사이트를 제공합니다. 갱신된 조사는 시장에 대한 COVID-19의 영향을 고려하고, 인사이트, 분석, 추정 및 예측을 제공합니다.

세계의 요로감염증(Urinary Tract Infection) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 시장 기회, COVID-19의 영향, 약제 클래스·임상 적응증·최종사용자·지역별 시장 규모 추정과 예측, 경쟁 상황, 주요 기업 개요 등 체계적인 정보를 제공합니다.

목차

제1장 서문

  • 조사 목적
  • 시장 세분화와 커버리지
  • 조사 대상 연도
  • 통화와 가격
  • 언어
  • 제한
  • 이해관계자

제2장 조사 방법

  • 조사 과정
    • 정의 : 조사 목적
    • 결정 : 조사 디자인
    • 준비 : 조사 기기
    • 수집 : 데이터 소스
    • 분석 : 데이터 해석
    • 책정 : 데이터 검증
    • 공개 : 조사 보고서
    • 반복 : 보고서 갱신
  • 조사 실행
    • 개시 : 조사 과정
    • 계획 : 조사 계획 작성
    • 실행 : 조사 실시
    • 검증 : 발견과 분석
    • 출판물 : 조사 보고
  • 조사 성과

제3장 주요 요약

  • 시장 전망
  • 약제 클래스 전망
  • 임상 적응증 전망
  • 최종사용자 전망
  • 지역 전망
  • 경쟁사 전망

제4장 시장 개요

  • COVID-19의 누적 영향

제5장 시장 인사이트

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 과제
  • Porters Five Forces 분석
    • 신규 참여업체의 위협
    • 대체품의 위협
    • 고객의 협상력
    • 공급 기업의 협상력
    • 업계의 경쟁

제6장 약제 클래스별

  • 아미노글리코사이드
  • 아졸
  • 퀴놀론
  • B-락탐

제7장 임상 적응증별

  • 방광염
  • 신우신염
  • 요도염

제8장 최종사용자별

  • 병원
  • 자기 관리

제9장 아메리카

  • 아르헨티나
  • 브라질
  • 캐나다
  • 멕시코
  • 미국

제10장 아시아태평양

  • 호주
  • 중국
  • 인도
  • 인도네시아
  • 일본
  • 말레이시아
  • 필리핀
  • 한국
  • 태국

제11장 유럽, 중동 및 아프리카

  • 프랑스
  • 독일
  • 이탈리아
  • 네덜란드
  • 카타르
  • 러시아
  • 사우디아라비아
  • 남아프리카공화국
  • 스페인
  • 아랍에미리트
  • 영국

제12장 경쟁 상황

  • FPNV 포지셔닝 매트릭스
    • 상한
    • 사업 전략
    • 제품 만족도
  • 시장 순위 분석
  • 시장 점유율 분석
  • 경쟁사 SWOT 분석
  • 경쟁 시나리오
    • 합병과 인수
    • 합의, 협업 및 파트너십
    • 신제품 발매와 강화
    • 투자와 자금 조달
    • 상, 표창, 확대

제13장 기업 유저빌리티 개요

  • Allergan plc
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cipla Inc.
  • Eli Lilly and Company,
  • F. Hoffmann La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Merck & Co., Inc.
  • Mindray Medical International Limited
  • Mylan N.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Siemens Healthcare
  • Sun Pharmaceuticals Ltd.
  • Teva Pharmaceuticals
  • Urit Medical Electronic Group Co., Ltd.

제14장 부록

  • 논의 가이드
  • 라이선스와 가격
KSM 21.04.27

LIST OF FIGURES

  • FIGURE 1. GLOBAL URINARY TRACT INFECTION MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL URINARY TRACT INFECTION MARKET: RESEARCH EXECUTION
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2020 VS 2025 (USD MILLION)
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2025 (USD MILLION)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET: MARKET DYNAMICS
  • FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)
  • FIGURE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)
  • FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2025
  • FIGURE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, 2020 VS 2025 (USD MILLION)
  • FIGURE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, 2020 VS 2025 (USD MILLION)
  • FIGURE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, 2020 VS 2025 (USD MILLION)
  • FIGURE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY Β-LACTAM, 2020 VS 2025 (USD MILLION)
  • FIGURE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2020 VS 2025 (%)
  • FIGURE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2020 VS 2025 (USD MILLION)
  • FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2025
  • FIGURE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, 2020 VS 2025 (USD MILLION)
  • FIGURE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, 2020 VS 2025 (USD MILLION)
  • FIGURE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, 2020 VS 2025 (USD MILLION)
  • FIGURE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2020 VS 2025 (%)
  • FIGURE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2020 VS 2025 (USD MILLION)
  • FIGURE 26. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025
  • FIGURE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, 2020 VS 2025 (USD MILLION)
  • FIGURE 28. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, 2020 VS 2025 (USD MILLION)
  • FIGURE 29. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 30. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 31. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 32. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 33. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 34. CANADA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 35. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 36. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 37. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 38. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 40. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 41. CHINA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 42. INDIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 43. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 44. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 45. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 46. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 47. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 48. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 49. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 50. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 52. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 53. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 54. ITALY URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 55. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 56. QATAR URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 57. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 58. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 59. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 60. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 61. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 62. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 63. GLOBAL URINARY TRACT INFECTION MARKET: FPNV POSITIONING MATRIX
  • FIGURE 64. GLOBAL URINARY TRACT INFECTION MARKET: MARKET SHARE ANALYSIS
  • FIGURE 65. GLOBAL URINARY TRACT INFECTION MARKET: COMPETITOR SWOT ANALYSIS
  • FIGURE 66. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL URINARY TRACT INFECTION MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. CURRENCY CONVERSION RATES
  • TABLE 2. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY Β-LACTAM, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. CANADA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. CHINA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. INDIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. ITALY URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. QATAR URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. GLOBAL URINARY TRACT INFECTION MARKET: SCORES
  • TABLE 103. GLOBAL URINARY TRACT INFECTION MARKET: BUSINESS STRATEGY
  • TABLE 104. GLOBAL URINARY TRACT INFECTION MARKET: PRODUCT SATISFACTION
  • TABLE 105. GLOBAL URINARY TRACT INFECTION MARKET: RANKING
  • TABLE 106. GLOBAL URINARY TRACT INFECTION MARKET: MERGER & ACQUISITION
  • TABLE 107. GLOBAL URINARY TRACT INFECTION MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 108. GLOBAL URINARY TRACT INFECTION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 109. GLOBAL URINARY TRACT INFECTION MARKET: INVESTMENT & FUNDING
  • TABLE 110. GLOBAL URINARY TRACT INFECTION MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 111. GLOBAL URINARY TRACT INFECTION MARKET: LICENSE & PRICING

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Urinary Tract Infection Market is expected to grow from USD 7,127.98 Million in 2020 to USD 9,488.14 Million by the end of 2025.

2. The Global Urinary Tract Infection Market is expected to grow from EUR 6,249.95 Million in 2020 to EUR 8,319.38 Million by the end of 2025.

3. The Global Urinary Tract Infection Market is expected to grow from GBP 5,556.21 Million in 2020 to GBP 7,395.94 Million by the end of 2025.

4. The Global Urinary Tract Infection Market is expected to grow from JPY 760,736.35 Million in 2020 to JPY 1,012,625.05 Million by the end of 2025.

5. The Global Urinary Tract Infection Market is expected to grow from AUD 10,350.77 Million in 2020 to AUD 13,778.04 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Urinary Tract Infection to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug Class, the Urinary Tract Infection Market studied across Aminoglycosides, Azoles, Quinolones, and B-lactam.

Based on Clinical Indication, the Urinary Tract Infection Market studied across Cystitis, Pyelonephritis, and Urethritis.

Based on End User, the Urinary Tract Infection Market studied across Hospitals and Self-Administered.

Based on Geography, the Urinary Tract Infection Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Urinary Tract Infection Market including Allergan plc, AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Cipla Inc., Eli Lilly and Company,, F. Hoffmann La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Merck & Co., Inc., Mindray Medical International Limited, Mylan N.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Siemens Healthcare, Sun Pharmaceuticals Ltd., Teva Pharmaceuticals, and Urit Medical Electronic Group Co., Ltd..

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch™FPNV Positioning Matrix:

The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the Urinary Tract Infection Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch™Competitive Strategic Window:

The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Urinary Tract Infection Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Urinary Tract Infection Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Urinary Tract Infection Market?

4. What is the competitive strategic window for opportunities in the Global Urinary Tract Infection Market?

5. What are the technology trends and regulatory frameworks in the Global Urinary Tract Infection Market?

6. What are the modes and strategic moves considered suitable for entering the Global Urinary Tract Infection Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Define: Research Objective
    • 2.1.2. Determine: Research Design
    • 2.1.3. Prepare: Research Instrument
    • 2.1.4. Collect: Data Source
    • 2.1.5. Analyze: Data Interpretation
    • 2.1.6. Formulate: Data Verification
    • 2.1.7. Publish: Research Report
    • 2.1.8. Repeat: Report Update
  • 2.2. Research Execution
    • 2.2.1. Initiation: Research Process
    • 2.2.2. Planning: Develop Research Plan
    • 2.2.3. Execution: Conduct Research
    • 2.2.4. Verification: Finding & Analysis
    • 2.2.5. Publication: Research Report
  • 2.3. Research Outcome

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Class Outlook
  • 3.4. Clinical Indication Outlook
  • 3.5. End User Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes and kidney stones
      • 5.1.1.2. Rise in the awareness among people regarding urinary tract infections owing to rising healthcare expenditure
      • 5.1.1.3. Emergence of portable and battery-operated urinary tract infections devices
    • 5.1.2. Restraints
      • 5.1.2.1. Complicated regulated monitoring
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in adoption of urinary tract infections in emerging economies
      • 5.1.3.2. Rise in R&D of a novel class of antibiotics for urinary tract infections
    • 5.1.4. Challenges
      • 5.1.4.1. Complex clinical trials for designing antibacterial drugs that require an informative, ethical, and scientific approach
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Global Urinary Tract Infection Market, By Drug Class

  • 6.1. Introduction
  • 6.2. Aminoglycosides
  • 6.3. Azoles
  • 6.4. Quinolones
  • 6.5. B-lactam

7. Global Urinary Tract Infection Market, By Clinical Indication

  • 7.1. Introduction
  • 7.2. Cystitis
  • 7.3. Pyelonephritis
  • 7.4. Urethritis

8. Global Urinary Tract Infection Market, By End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Self-Administered

9. Americas Urinary Tract Infection Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Urinary Tract Infection Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. South Korea
  • 10.10. Thailand

11. Europe, Middle East & Africa Urinary Tract Infection Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis
  • 12.4. Competitor SWOT Analysis
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Allergan plc
  • 13.2. AstraZeneca plc
  • 13.3. Bayer AG
  • 13.4. Boehringer Ingelheim GmbH
  • 13.5. Cipla Inc.
  • 13.6. Eli Lilly and Company,
  • 13.7. F. Hoffmann La Roche Ltd
  • 13.8. GlaxoSmithKline plc
  • 13.9. Johnson & Johnson
  • 13.10. Merck & Co. Inc.
  • 13.11. Merck & Co., Inc.
  • 13.12. Mindray Medical International Limited
  • 13.13. Mylan N.V.
  • 13.14. Novartis AG
  • 13.15. Novo Nordisk A/S
  • 13.16. Pfizer Inc.
  • 13.17. Siemens Healthcare
  • 13.18. Sun Pharmaceuticals Ltd.
  • 13.19. Teva Pharmaceuticals
  • 13.20. Urit Medical Electronic Group Co., Ltd.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
Back to Top
전화 문의
F A Q